Warning letter
Nexagen, LLC: warning letter of Oct 6, 2017
FDA warning letter 527933 · Atlanta District Office
Key facts
| Reference number | 527933 |
|---|---|
| Company | Nexagen, LLC |
| Subject | CGMP/Dietary Supplement/Adulterated |
| Issue date | Oct 6, 2017 |
| Posted date | Oct 31, 2017 |
| Issuing office | Atlanta District Office |
| Product type | Food/Cosmetics |
| CFR sections cited | 111.75, 111.103, 111.260, 111.453, 111.503, 111.553, 111.560, 111.570, 111.70(a), 111.70(g), 111.155(c), 111.205(b)(1) and 10 more |
| Inspection city | Fayetteville |
| Inspection ZIP | 30214 |
| Inspection start date | Apr 3, 2017 |
| Letter on fda.gov | fda.gov |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: